Milestone payment for ALK following new Japanese study
The Japanese partner of Danish company ALK-Abello has started new, late-stage clinical trials with the allergy company’s innovative hay fever and asthma pill. It triggers a milestone payment for the Danish company.
af LEONORA BECK
Two newly initiated phase 2/3 studies will spell extra profit for ALK-Abello. The Danish pharmaceutical group’s Japanese partner has begun concluding clinical trials with the pill Mitizax against hay fever and asthma caused by house dust mites.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
